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Background
The first Department of Clinical Haematology in Myanmar was established in 1994, and since then,
specific treatments have been offered for a variety of hematological disorders except for the option of
hematopoietic stem cell transplantation (HSCT). Although there was improvement in health care, there
were many patients suffering from incurable diseases due to the lack of a HSCT program, which is
extremely costly and complicated for a developing country.
Limitations in Myanmar
Myanmar has very limited human resources with ,20 hematologists, old and young, covering a
population of.50 million. Almost all hospitals are under the Ministry of Health, and HSCT is not a priority
compared with the burden of infectious diseases and nutritional deficiencies. Red tape and strict
regulations under the previous military government were also not favorable for new projects.
Disease burden
Myanmar has a high burden of hematological disorders, with a large number of hematologic
malignancies in particular with increasing numbers of new cases each year (Figure 1).
Role of the Myanmar Society of Haematology
In 2003, Myanmar hematologists together with pathologists and clinicians interested in hematology
established the Myanmar Society of Haematology (MSH) and started academic activities. Overseas
speakers were invited at the local conferences to educate Myanmar clinicians on HSCT. The MSH and
eminent transplant physicians visiting Myanmar advocated for HSCT to administrative authorities,
including the Minister of Health. In 2010, a leukemia-lymphoma special interest group was formed, under
which dedicated members interested in initiating a HSCT started capacity-building initiatives.
Hematologists and trainees were also funded to attend overseas meetings and studies.
Role of the Ministry of Health
Along with the transition from a military to a democratic government, the health budget was improved,
and the Ministry of Health was able to provide funding for drugs and equipment for apheresis, flow
cytometry, and training.
Helping hands from countries in the Asia-Pacific region
Transplant physicians from Singapore, Thailand, India, Australia, Hong Kong, and Japan, who are also
members of the Asia-Pacific Blood and Marrow Transplant Group (APBMT) voluntarily visited Myanmar,
gave advice, educational talks, and knowledge updates, and shared their experience to help initiate a
transplant program in Myanmar (Tables 1 and 2). Volunteers from the Singapore Health Sciences
Authorities have come regularly since 2004 to help develop blood group serology and transfusion
services in Myanmar.
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Figure 1. Trends in hematological disorders at Yangon General Hospital (1996 to 2010), showing increasing numbers of new cases of aplastic anemia and
hematologic malignancies in recent years.
Table 1. International experts visiting Myanmar in support of transplant capacity-building
Period Visit of volunteers and experts who are members of APBMT Activities
2004-2014 Regular visits by a team of volunteer hematologists and blood bank technicians from
Singapore International Foundation led by a transplant physician to Yangon and
Mandalay
Blood group serology workshops and support on blood safety and transfusion services
in Myanmar
Lectures on stem cell transplantation, case discussions
Situation analysis and advocacy to authorities
Advice on individual cases for transplant
2009-2013 Frequent visits by hematologist/transplant physicians from Siriraj Hospital, Thailand,
and the Thai Society of Haematology
Meeting with MSH for collaboration and offering training for doctors, nurses, and
laboratory personnel
Continuing medical education lectures, case consultation
Education symposium
Site visit and advice for initiating program
2009, 2011 Visit by hematologist/transplant physicians from Christian Medical College, Vellore,
India, and Tata Memorial Hospital, Mumbai, India
Education symposium, meeting with MSH for collaboration and advice on initiating
transplant program
Site visit and advice for initiating program
2013 Visit by hematologist/transplant physicians from Hong Kong Education symposium, site visit, and advice
2013 A team of volunteer hematologist/transplant physicians and infectious disease
specialists from St. Vincent’s Hospital, Sydney, New South Wales, Australia
Educational talks on various topics related to HSCT, including infection control and
management of infectious complications
Courtesy call to Minister of Health and advocacy on HSCT
Technical advice, advice on specification of flow cytometer, and apheresis machine
Advice on individual cases for transplant
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Leadership from the Worldwide Network for
Blood and Marrow Transplantation
and APBMT
By participating in annual meetings of the APBMT since 2010,
knowledge and networks were widened, and experience among the
member countries could be shared.
The First International Workshop on HSCT in Emerging Countries,
organized by the Worldwide Network for Blood and Marrow
Transplantation, was held in 2011 in Vietnam. It was a landmark for
HSCT-related activities in the region.
Transplant team and the first HSCT case
in Myanmar
In 2014, the very first case of autologous HSCT in Myanmar was
successfully performed for a patient with multiple myeloma without
cryopreservation in a resource-poor setting.
The unique feature of the first transplant case in Myanmar is that the
transplant team, made up of dedicated members of the MSH
working in different departments and specialized in different areas,
came to make the joint effort to initiate the first step.
Current status of HSCT in Myanmar
From May 2014 to October 2016, a total of 6 cases of autologous
HSCT for multiple myeloma were performed (Table 3). All patients
except 1 achieved a minimum of 1 year of relapse-free survival at
this time.
Conclusions
Myanmar has spent several years overcoming many barriers to start
an HSCT program. The successful start of this program was made
possible with collaboration and support from APBMT members,
especially in building the capacity of the Myanmar transplant team.
We need to strengthen our transplant capacity to cover not only
autologous but also allogeneic transplantation and to cover
autologous transplantation for other diseases by improving, for
example, cryopreservation techniques, management of posttrans-
plant complications, and data management systems.
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Table 2. Foreign centers supporting capacity building for HSCT in
Myanmar
Period Transplant center Trainees, n
2008-2013 Bone Marrow Transplant
Unit and Transfusion Medicine
Department, Siriraj Hospital,
Thailand
Transplant physician, 2
Transplant nurses, 3
Apheresis/blood bank
personnel, 2
Laboratory personnel for
enumeration of stem cells, 2
2013 Christian Medical College, Vellore, India Transplant physician, 1
Transplant nurse, 1
2014 University of Maryland Greenebaum
Cancer Center, Baltimore, MD
Transplant physician, 1
2015 St. Vincent’s Hospital, Sydney,
New South Wales, Australia
Cryopreservation, 1
Table 3. Characteristics of the patients who underwent autologous
stem cell transplantation in Myanmar from 2014 to 2016
Age 53-62 years
Sex 4 males and 2 females
Myeloma stage Durie-Salmon stage IIIA in 5 patients, 1 IIIA;
International Staging System stage II-III
Induction Bortezomib-thalidomide-dexamethasone induction
Remission status prior
transplant
Stringent complete remission (CR) to very good
partial remission (VGPR)
Time from diagnosis to
transplant
6 months to 5 years
Mobilization Granulocyte colony-stimulating factor 10 mg/kg per
day subcutaneously, except 1 case of 15 mg/kg per
day; high-dose etoposide in 1 case
Peripheral blood stem
cell harvest
Day 5-7
Storage In pharmaceutical refrigerator, at 2-4˚C, for 24-72
hours
Conditioning High-dose melphalan (dose, 110-200 mg/m2)
Stem cell reinfusion Reinfuse after high-dose melphalan without
cryopreservation after 24-72 hours
Stem cell dose 1.45 3 106-4.75 3 106/kg
Engraftment Neutrophil engraftment: day 10-11; platelet
engraftment: day 14-18
Figure 2. Map showing the location of Myanmar in Asia.
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Figure 3. An invited speaker at an MSH conference.
Figure 4. Transplant physicians from Asia and the Pacific region visiting
Myanmar for capacity building.
Figure 5. Hematologists from Myanmar attending an APBMT congress and
the First International Workshop on HSCT in Emerging Countries.
Figure 6. Myanmar blood and marrow transplant team.
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Figure 7. The hematology department at North Okkalapa General Hospital. The first HSCT in Myanmar was done at this hospital in a resource-poor setting. A power
generator was used to ensure a stable supply of electricity.
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